All In Biotech

Drug Trial Radar · NCT03453112

Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.

A 12-week, Multicenter, Randomized, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster 100/6mg NEXThaler, 2 Inhalations b.i.d, Versus Foster 100/6mg pMDI, 2 Puffs b.i.d in Patients With Controlled Asthma.

Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 494 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

494

Actual

Start

Oct 9, 2017

Primary completion

Dec 28, 2021

Study completion Dec 28, 2021

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Mar 5, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective To demonstrate the non-inferiority of Foster® NEXThaler® 100/6 µg versus (vs.) Foster® pressurised metered dose inhaler (pMDI) 100/6 µg in terms of pulmonary function (change from baseline to the entire treatment period in average pre-dose morning peak expiratory flow \[PEF\]) in asthmatic patients. Secondary Objectives To evaluate the effect of the test treatments in terms of additional lung function parameters and clinical outcome measures, and to assess the safety and tolerability.

Conditions

  • Asthma

Interventions

  • Foster 100/6µg NEXThalerDrug

    A fixed combination of beclometasone dipropionate 100 µg and formoterol fumarate 6 µg per actuation, delivered via a breath-actuated dry powder inhaler (DPI).

  • Foster 100/6µg pMDIDrug

    A fixed combination of beclometasone dipropionate 100 µg and formoterol fumarate 6 µg per actuation, delivered via a pressurized metered-dose inhaler (pMDI) with HFA\_134a propellant.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to End of Treatment Period in Average Pre-dose Morning Peak Expiratory Flow (PEF)Time frame: Baseline (Week 0, Visit 3) and Week 12 (EoT)

Locations

51 sites in 1 country. Site status is shown where the registry gives one.

  • Chiesi Clinical Trial site 15672

    Beijing, China

  • Chiesi clinical Trial site 15636

    Beijing, China

  • Chiesi Clinical Trial site 15638

    Chongqing, China

  • Chiesi Clinical Trial site 15670

    Guizhou, China

  • Chiesi clinical Trial Site 15611

    Hebei, China

  • Chiesi Clinical trial site 15660

    Jilin City, China

  • Chiesi Clinical Trial site 15628

    Shanghai, China

  • Chiesi clinical trial site 15637

    Shanghai, China

  • Chiesi Clinical Trial site 15666

    Shenzhen, China

  • Chiesi clinical Trial site 15633

    Sichuan, China

  • Chiesi Clinical Trial site 15669

    Ürümqi, China

  • Chiesi Clinical Trial site 15641

    Hefei, Anhui, China

  • Chiesi Clinical Trial site 15682

    Beijing, Beijing Municipality, China

  • Chiesi Clinical Trial site 15663

    Beijing, Beijing Municipality, China

  • Chiesi Clinical Trial site 15662

    Foshan, Guangdong, China

  • Chiesi Clinical Trial site 15671

    Guangzhou, Guangdong, China

  • Chiesi clinical Trial Site 15610

    Guangzhou, Guangdong, China

  • Chiesi clinical Trial site 15656

    Guangzhou, Guangdong, China

  • Chiesi Clinical Trial site 15668

    Guangzhou, Guangdong, China

  • Chiesi Clinical Trial site 15677

    Huizhou, Guangdong, China

  • Chiesi Clinical Trial site 15683

    Shenzhen, Guangdong, China

  • Chiesi Clinical Trial site 15608

    Shenzhen, Guangdong, China

  • Chiesi Clinical Trial site 15607

    Zhanjiang, Guangdong, China

  • Chiesi Clinical Trial site 15610

    Guangzhou, Guangzhou, China

  • Chiesi Clinical Trial site 15673

    Haikou, Hainan, China

  • Chiesi Clinical Trial site 15678

    Qiqihar, Heilongjiang, China

  • Chiesi Clinical Trial site 15681

    Xinxiang, Henan, China

  • Chiesi Clinical Trial site 15679

    Zhengzhou, Henan, China

  • Chiesi Clinical Trial site 15614

    Wuhan, Hubei, China

  • Chiesi Clinical Trial site 15661

    Wuhan, Hubei, China

  • Chiesi Clinical Trial site 15675

    Hengyang, Hunan, China

  • Chiesi Clinical Trial site 15643

    Changzhou, Jiangsu, China

  • Chiesi Clinical Trial site 15674

    Pingxiang, Jiangxi, China

  • Chiesi Clinical Trial site 15676

    Jilin City, Jilin, China

  • Chiesi clinical Trial site 15621

    Shenyang, Liaoning, China

  • Chiesi clinical Trial site 15619

    Nanchang, Nanchang, China

  • Chiesi Clinical Trial site 15650

    Hohhot, Neimenggu, China

  • Chiesi clinical Trial site 15659

    Hohhot, Neimenggu, China

  • Chiesi Clinical Trial site 15630

    Shanghai, Shanghai Municipality, China

  • Chiesi Clinical Trial site 15664

    Shanghai, Shanghai Municipality, China

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.